Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
CONTEXT: FGF23 measurement may have a role in the management of patients with chronic kidney disease (CKD). OBJECTIVE: Our objective was to study the biological variability of plasma intact FGF23 (iFGF23) and C-terminal FGF23 (cFGF23) concentrations. DESIGN: Plasma samples were taken from 12 healthy adults at multiple time points on 2 consecutive days to assess diurnal variability of FGF23 concentrations. Early-morning fasting and nonfasting samples were also taken over a 6-wk period to estimate components of biological variation. Samples from 170 volunteers were used to define reference intervals. FGF23 concentrations were measured by commercial ELISA. Western blotting was used to analyze FGF23 species from the plasma of healthy adults and patients with predialysis CKD and those undergoing dialysis. PARTICIPANTS AND SETTING: A total of 180 healthy adults and 18 adults with stage 3-5D CKD participated in this study at a hospital research unit. MAIN OUTCOME MEASURE: Estimates were made of the biological variability of plasma FGF23 concentrations. RESULTS: iFGF23, but not cFGF23, showed significant diurnal variation. cFGF23 had a significantly lower intra-individual variation than iFGF23 (8.3 vs. 18.3%) but higher inter-individual variation than iFGF23 (28.9 vs. 19.2%). Fourteen samples would be needed to estimate an individual's homeostatic set point (within 10%) for iFGF23 compared with only three samples for cFGF23. Using Western blotting, C-terminal FGF23 fragments were detected in the plasma of individuals with normal renal function and at all stages of renal disease. The percent cFGF23 was significantly higher in those without renal impairment (P < 0.001) and was positively correlated with plasma phosphate concentration in those with normal renal function. CONCLUSIONS: The high intra-individual biological variability of iFGF23 may limit its clinical use as a diagnostic or management tool. Risk-related thresholds may be more appropriate for clinical decision making based on cFGF23 measurements than conventional reference intervals. FGF23 cleavage pathways may be an important natural regulatory mechanism for phosphate control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Larsson, T., Nisbeth, U. L. F., Ljunggren, Ö., Jüppner, H., & Jonsson, K. B. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00328.x · Cited by 689
Dietary Phosphorus Regulates Serum Fibroblast Growth Factor-23 Concentrations in Healthy Men
Antoniucci, D. M., Yamashita, T., & Portale, A. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0021 · Cited by 421
Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men
Nishida, Y., Taketani, Y., Yamanaka-Okumura, H., Imamura, F., Taniguchi, A., Sato, T., Shuto, E., Nashiki, K., Arai, H., Yamamoto, H., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5002000 · Cited by 243
Effects of Dietary Phosphate and Calcium Intake on Fibroblast Growth Factor-23
Vervloet, M. G., van Ittersum, F. J., Büttler, R. M., Heijboer, A. C., Blankenstein, M. A., & ter Wee, P. M. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04730510 · Cited by 218 · cited 1×
“Earlier attempts to define diurnal variation of iFGF23 have been inconsistent (24, 25) and were possibly affected by stability issues (14).”
Background
Cited by
Blau, J. E., Bauman, V., Conway, E. M., Piaggi, P., Walter, M. F., Wright, E. C., Bernstein, S., Courville, A. B., Collins, M. T., Rother, K. I., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99123 · Cited by 172
on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Bottani, M., Banfi, G., Guerra, E., Locatelli, M., Aarsand, A. K., Coşkun, A., Díaz-Garzón, J., Fernandez-Calle, P., Sandberg, S., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-19-4498 · Cited by 15
“Considering the studies performed in healthy populations: 2 declared to assess the biointact PTH (PTH 1-84) BV using third-generation assays (15,19); 4 the intact PTH BV using second-generation assays (12,15,19,21), whereas 4 did not specify the assay used for PTH evaluation and thus it is not clear whether the obtain…”
BackgroundMethodEgli-Spichtig, D., Hamid, A. K., Arroyo, E. M. P., Ketteler, M., Wiecek, A., Rosenkranz, A. R., Pasch, A., Lorenz, H., Hellmann, B., Karus, M., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad040 · Cited by 9
Metadata
- Authors
- Smith, E. R., Cai, M. M., McMahon, L. P., & Holt, S. G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-09-01
- Volume
- 97
- Issue
- 9
- Pages
- 3357-3365
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2146045604
- Cited by
- 214
- References
- 5
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements. https://app.cochat.ai/papers/10.1210/jc.2012-1811
- The paper
- Smith, E. R., Cai, M. M., McMahon, L. P., & Holt, S. G. (2012). Biological Variability of Plasma Intact and C-Terminal FGF23 Measurements. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-1811
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.